Recommendations for Hepatitis B Immunoglobulin and Antiviral Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation

Creative Commons License

AKARSU M., ÖNEM S., TURAN İ., Adali G., Akdogan M., Akyildiz M., ...Daha Fazla

TURKISH JOURNAL OF GASTROENTEROLOGY, cilt.32, sa.9, ss.712-719, 2021 (SCI-Expanded) identifier identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 32 Sayı: 9
  • Basım Tarihi: 2021
  • Doi Numarası: 10.5152/tjg.2021.21608
  • Dergi Adı: TURKISH JOURNAL OF GASTROENTEROLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.712-719
  • Anahtar Kelimeler: Hepatitis B, liver transplantation, recurrence, VIRUS RECURRENCE, IMMUNE GLOBULIN, SURFACE-ANTIGEN, NUCLEOS(T)IDE ANALOGS, VIRAL-HEPATITIS, PREVENTION, MANAGEMENT, LAMIVUDINE, EFFICACY, OUTCOMES
  • Hacettepe Üniversitesi Adresli: Evet

Özet

The combination of hepatitis B immunoglobulin and potent nucleos(t)ide analogs after liver transplantation is considered as the standard of care for prophylaxis against hepatitis B virus recurrence. However, the recommended doses, route of administration, and duration of HBIG administration remain unclear. Moreover, hepatitis B immunoglobulin-free prophylaxis with potent nucleos(t)ide analogs has shown promising disease outcomes in preventing hepatitis B virus recurrence. The current recommendations, produced by the Turkish Association for the Study of the Liver, Acute Liver Failure and Liver Transplantation Special Interest Group, suggest a reduced need for hepatitis B immunoglobulin administration with effective long-term suppression of hepatitis B virus replication using potent nucleos(t)ide analogs after liver transplantation.